Prof. Ronit Satchi-Fainaro (Ph.D.) is a Full Professor at Tel Aviv University, where she is head of the Cancer Research & Nanomedicine Laboratory, Director of the TAU Kahn 3D BioPrinting Initiative and holds the Kurt and Herman Lion Chair in Nanosciences and Nanotechnologies. She was recently appointed to be the next Director of Tel Aviv University Cancer Biology Research Center. She serves on the Board of Directors of Teva Pharmaceutical Industries Ltd., Board of Governors of Tel Aviv University, member of the Scientific Advisory Board (SAB) of the Blavatnik Center for Drug Discovery, the Israel Cancer Association, the Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR, Barcelona, Spain), The Rothschild Fellowships Committee, several VCs and editorial boards of scientific journals.
Her multidisciplinary research laboratory focuses on basic research elucidating the mechanisms underlying the switch from cancer dormancy leading to the discovery of new molecular targets to interrupt tumor-host interactions. Her approach is followed by the design of highly-selective targeting molecules integrating biology, chemistry, medicine, bioinformatics and nanotechnology to selectively guide drugs into pathological sites. Throughout, she has maintained an interest in understanding the biological rationale for the design of nanomedicines suitable for transfer into clinical testing. She published more than 120 manuscripts, 13 book chapters, edited 2 books, is named inventor on 55 patents, some of which were licensed to Pharmaceutical and Biotech companies, and has delivered over 450 lectures worldwide.
She is currently founding a spin-off company and is actively engaged in translational research with several industry partners and in science outreach. She was awarded numerous prestigious grants and prizes among them Fulbright, Rothschild, Wingate, Alon, Young Investigator Award of the European Association for Cancer Research, JULUDAN Prize for the Advancement of Technology in Medicine, the 2013 Teva Pharmaceutical Industries Founders Award for the Discovery of new molecular mechanisms and targets that would lead to new therapeutic approaches, The 2020 Youdim Family Prize for Excellence in Cancer Research, The 2020 Kadar Family Award for Outstanding Research and the 2020 Humboldt Foundation Bessel Research Prize.